CA3017963A1 - Compositions and methods for the treatment of a beta-catenin-associated disease or disorder - Google Patents

Compositions and methods for the treatment of a beta-catenin-associated disease or disorder Download PDF

Info

Publication number
CA3017963A1
CA3017963A1 CA3017963A CA3017963A CA3017963A1 CA 3017963 A1 CA3017963 A1 CA 3017963A1 CA 3017963 A CA3017963 A CA 3017963A CA 3017963 A CA3017963 A CA 3017963A CA 3017963 A1 CA3017963 A1 CA 3017963A1
Authority
CA
Canada
Prior art keywords
nucleic acid
catenin
inhibitor molecule
beta
acid inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3017963A
Other languages
English (en)
French (fr)
Inventor
Marc Abrams
Shanthi Ganesh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dicerna Pharmaceuticals Inc
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of CA3017963A1 publication Critical patent/CA3017963A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3017963A 2016-03-16 2017-03-15 Compositions and methods for the treatment of a beta-catenin-associated disease or disorder Pending CA3017963A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662309449P 2016-03-16 2016-03-16
US62/309,449 2016-03-16
US201662318529P 2016-04-05 2016-04-05
US62/318,529 2016-04-05
US201662365164P 2016-07-21 2016-07-21
US62/365,164 2016-07-21
PCT/US2017/022510 WO2017160983A1 (en) 2016-03-16 2017-03-15 Compositions and methods for the treatment of a beta-catenin-associated disease or disorder

Publications (1)

Publication Number Publication Date
CA3017963A1 true CA3017963A1 (en) 2017-09-21

Family

ID=59850959

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3017963A Pending CA3017963A1 (en) 2016-03-16 2017-03-15 Compositions and methods for the treatment of a beta-catenin-associated disease or disorder

Country Status (6)

Country Link
US (3) US10821112B2 (enExample)
EP (1) EP3429598A4 (enExample)
JP (2) JP6987084B2 (enExample)
AU (2) AU2017232496B2 (enExample)
CA (1) CA3017963A1 (enExample)
WO (1) WO2017160983A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017232496B2 (en) * 2016-03-16 2022-11-24 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
JP2021500026A (ja) * 2017-10-18 2021-01-07 ディセルナ ファーマシューティカルズ インコーポレイテッド βカテニン核酸阻害剤分子
AU2019205904A1 (en) 2018-01-05 2020-06-18 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy
JP7535047B2 (ja) * 2018-12-12 2024-08-15 ディセルナ ファーマシューティカルズ インコーポレイテッド トリループを含む二本鎖核酸インヒビター分子
WO2020226960A1 (en) * 2019-05-03 2020-11-12 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
WO2023122316A2 (en) * 2021-12-23 2023-06-29 Aligos Therapeutics, Inc. SPLICE SWITCH OLIGONUCLEOTIDE (SSO) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF
US20250152677A1 (en) * 2022-02-14 2025-05-15 Institut National de la Santé et de la Recherche Médicale Treatment of liver cancers by disrupting the beta-catenin/tcf-4 binding site located upstreatm of meg3 in the dlk1/dio3 locus
CN119923258A (zh) * 2022-10-21 2025-05-02 递归医药公司 在wnt通路肿瘤阻抑基因中具有突变的癌症的治疗
WO2025147555A1 (en) * 2024-01-05 2025-07-10 Recursion Pharmaceuticals, Inc. Rec-4881 (tak-733) for use in treating or preventing colorectal cancer and related diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004535388A (ja) * 2001-04-30 2004-11-25 ターゲティッド ジェネティクス コーポレイション 脂質含有薬物送達複合体およびそれらの生成方法
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US20100055782A1 (en) 2007-03-02 2010-03-04 Mdrna, Inc. Nucleic acid compounds for inhibiting myc gene expression and uses thereof
DK2591105T3 (en) 2010-07-06 2017-07-31 Dicerna Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR SPECIFIC INHIBITION OF BETA-CATENIN USING DOUBLE-STRENGTH RNA
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
WO2013066944A2 (en) * 2011-10-31 2013-05-10 The Board Of Regents Of The University Of Texas System Biomarkers for cancer characterization and treatment
BR112014016870A2 (pt) 2012-01-09 2017-06-27 Huesken Dieter composições orgânicas para tratar doenças relacionadas com beta-catenina
JP2015529467A (ja) 2012-09-14 2015-10-08 ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 二本鎖ｒｎａによるｍｙｃの特異的阻害に関する方法および組成物
US10201556B2 (en) * 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
CN105163584B (zh) 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
TWI839690B (zh) * 2013-07-12 2024-04-21 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合的用途
KR102186363B1 (ko) 2013-09-06 2020-12-04 삼성전자주식회사 c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물
KR102192591B1 (ko) 2013-09-09 2020-12-18 삼성전자주식회사 c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물
WO2015051252A1 (en) 2013-10-03 2015-04-09 Duke University Compositions and methods for treating cancer with jak2 activity
US9895312B2 (en) 2014-04-08 2018-02-20 Pablo E. Vivas-Mejia Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
AU2017232496B2 (en) * 2016-03-16 2022-11-24 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder

Also Published As

Publication number Publication date
US11504374B2 (en) 2022-11-22
AU2023200960A1 (en) 2023-04-27
US20210015820A1 (en) 2021-01-21
JP2022033848A (ja) 2022-03-02
EP3429598A1 (en) 2019-01-23
EP3429598A4 (en) 2020-04-01
US20190070180A1 (en) 2019-03-07
AU2017232496A1 (en) 2018-10-04
US20230190753A1 (en) 2023-06-22
US10821112B2 (en) 2020-11-03
AU2017232496B2 (en) 2022-11-24
WO2017160983A1 (en) 2017-09-21
JP7321236B2 (ja) 2023-08-04
JP2019512543A (ja) 2019-05-16
JP6987084B2 (ja) 2021-12-22

Similar Documents

Publication Publication Date Title
US11504374B2 (en) Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
EP3240796B1 (en) Rna interference compositions and methods for malignant tumors
JP7392954B2 (ja) トリプルネガティブ乳癌の治療方法
AU2020253823A1 (en) Compositions and methods for the treatment of KRAS associated diseases or disorders
WO2021184990A1 (zh) 一种增敏剂药物及药物组合及应用
US20150307885A1 (en) Multiple targeted rnai for the treatment of cancers
CN1703229B (zh) 治疗前列腺和其他癌的组合物和其制备药物的用途
Hsi et al. Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling
JP2016204365A (ja) Ｂｒａｆ遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物
WO2017190695A1 (zh) 一种抑制EGFR基因表达的siRNA及其前体和应用
KR20200052294A (ko) Setd2의 저해에 의한 암의 치료 방법
JP5406024B2 (ja) Ｂｃｌ−ＸＬ特異的ｓｉＮＡを用いる癌治療法
TW201728334A (zh) 用於治療癌症之組合物及方法
Liu et al. MicroRNA-708 inhibits the proliferation and chemoresistance of pancreatic cancer cells
WO2017160797A1 (en) Combination therapy with c-myc nucleic acid inhibitors and selective cdk7 inhibitors
JP2026504743A (ja) 膵管腺癌に対するｅｇｆｒ、ｒａｆ１、およびｓｔａｔ３を阻害する三剤併用療法
JP5762103B2 (ja) 頭頸部癌及び食道癌用抗癌剤及び増強剤
WO2019107487A1 (ja) マイクロｒｎａ及びその誘導体を有効成分とする医薬組成物
Rubio-San-Simon et al. A Randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in patients with relapsed or refractory Ewing sarcoma
JP2025541376A (ja) Ｋｒａｓ発現の阻害のための組成物、およびその使用方法
US8927598B2 (en) Treating oncogenic Ras driven cancers

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220217

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20240916

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250916

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260221

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260428